Phenotypes Associated with This Genotype

Genotype
MGI:4944272

• Allelic Composition: Pgr^tm2(cre)Lyd/Pgr⁺; Pten^tm1Hwu/Pten^tm1Hwu
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:218222 )

♀ • mice display a progressive decline in survival due to the development of endometrial cancer; all mice die by ~50 weeks of age

reproductive system

increased endometrial carcinoma incidence ( J:162027 , J:218222 )

♀ • mice develop endometrial adenocarcinoma with invasion into the myometrium at 2 months of age (J:162027)

♀ • mice develop endometrial adenocarcinoma at 2 and 3 months of ages as characterized by neoplastic endometrial glands invading through the myometrium (J:218222)

♀ • treatment with U0126, an effective inhibitor of MAPK/ERK kinase, suppresses endometrial cancer progression, as shown by the arrest of tumors at the hyperplastic or normal stage (J:218222)

endometrium hyperplasia ( J:162027 )

♀ • mice exhibit endometrial hyperplasia at 4 weeks of age

decreased uterus weight ( J:218222 )

♀ • mice treated with U0126, an effective inhibitor of MAPK/ERK kinase, display a significant decrease in uterine weight relative to mice treated with vehicle

increased uterus weight ( J:162027 , J:218222 )

♀ • increase in uterine weight at 2 weeks of age (J:162027)

♀ • at 3 months of age, mice show a significant increase in uterine/body weight ratio relative to controls (J:218222)

abnormal uterus physiology ( J:162027 )

♀ • proliferation is increased in the endothelium epithelium

neoplasm

increased endometrial carcinoma incidence ( J:162027 , J:218222 )

♀ • mice develop endometrial adenocarcinoma with invasion into the myometrium at 2 months of age (J:162027)

♀ • mice develop endometrial adenocarcinoma at 2 and 3 months of ages as characterized by neoplastic endometrial glands invading through the myometrium (J:218222)

♀ • treatment with U0126, an effective inhibitor of MAPK/ERK kinase, suppresses endometrial cancer progression, as shown by the arrest of tumors at the hyperplastic or normal stage (J:218222)

increased papilloma incidence ( J:218222 )

♀ • mice develop vaginal papillomas